Chapter 35 : Molecular Detection and Characterization of HIV-1

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Molecular Detection and Characterization of HIV-1, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816834/9781555814977_Chap35-1.gif /docserver/preview/fulltext/10.1128/9781555816834/9781555814977_Chap35-2.gif


This chapter focuses on the available molecular tests for diagnosis, monitoring, and management of HIV-1-infected individuals. It also focuses on molecular methods as they apply to the diagnosis and management of human immunodeficiency virus type 1 (HIV- 1). The guidelines for initiation of therapy based on viral load have changed as one's understanding of disease progression at higher CD4 cell counts has improved. Combination therapy using drugs from multiple classes has been the most effective approach to controlling viral replication. There are several FDA-approved assays for the detection, quantification, and characterization of HIV-1, and this field has expanded recently with the approval of real-time RTPCR viral load tests. A section covers conventional and real-time viral load tests, RNA and proviral DNA tests for the detection of HIV-1, resistance testing, and the tropism assay. The Amplicor monitor test was modified in a study comparing viral load values between the conventional and real-time tests using a different extraction method than recommended by the manufacturer, and it is unclear what impact this may have had on the viral load values. The current recommendations for specimen collection and processing for HIV-1 resistance testing are the same as for viral load testing. Genotypic resistance testing is one of the most complex tests performed in the molecular microbiology laboratory and involves multiple technical steps to generate the sequence as well as interpretation of the sequencing data. Currently, the systems for viral load testing require high capital investment in instrumentation along with reliable electricity and pure water.

Citation: Caliendo A, Kraft C. 2011. Molecular Detection and Characterization of HIV-1, p 541-556. In Persing D, Tenover F, Tang Y, Nolte F, Hayden R, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555816834.ch35

Key Concept Ranking

Human immunodeficiency virus 1
Highly Active Antiretroviral Therapy
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Simplified HIV-1 genome with its nine genes and the long terminal repeat regions. The enzymes reverse transcriptase, protease, and integrase are all encoded within the gene.

Citation: Caliendo A, Kraft C. 2011. Molecular Detection and Characterization of HIV-1, p 541-556. In Persing D, Tenover F, Tang Y, Nolte F, Hayden R, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555816834.ch35
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Overview of HIV-1 resistance testing.

Citation: Caliendo A, Kraft C. 2011. Molecular Detection and Characterization of HIV-1, p 541-556. In Persing D, Tenover F, Tang Y, Nolte F, Hayden R, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555816834.ch35
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Baxter, J. D.,, D. L. Mayers,, D. N. Wentworth,, J. D. Neaton,, M. L. Hoover,, M. A. Winters,, S. B. Mannheimer,, M. A. Thompson,, D. I. Abrams,, B. J. Brizz,, J. P. Ioannidis, and, T. C. Merigan. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14:F83F93.
2. Berger, A.,, L. Scherzed,, M. Sturmer,, W. Preiser,, H. W. Doerr, and, H. F. Rabenau. 2005. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J. Clin. Virol. 33:4351.
3. Bossi, P.,, G. Peytavin,, H. Ait-Mohand,, C. Delaugerre,, N. Ktorza,, L. Paris,, M. Bonmarchand,, R. Cacace,, D. J. David,, A. Simon,, C. Lamotte,, A. G. Marcelin,, V. Calvez,, F. Bricaire,, D. Costagliola, and, C. Katlama. 2004. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 5:352359.
4. Brambilla, D.,, C. Jennings,, G. Aldrovandi,, J. Bremer,, A. M. Comeau,, S. A. Cassol,, R. Dickover,, J. B. Jackson,, J. Pitt,, J. L. Sullivan,, A. Butcher,, L. Grosso,, P. Reichelderfer, and, S. A. Fiscus. 2003. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J. Clin. Microbiol. 41:18881893.
5. Brambilla, D.,, S. Leung,, J. Lew,, J. Todd,, S. Herman,, M. Cronin,, D. E. Shapiro,, J. Bremer,, C. Hanson,, G. V. Hillyer,, G. D. McSherry,, R. S. Sperling,, R. W. Coombs, and, P. S. Reichelderfer. 1998. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J. Clin. Microbiol. 36:311314.
6. Braun, P.,, R. Ehret,, F. Wiesmann,, F. Zabbai,, M. Knickmann,, R. Kuhn,, S. Thamm,, G. Warnat, and, H. Knechten. 2007. Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin. Chem. Lab. Med. 45:9399.
7. Cao, Y.,, D. D. Ho,, J. Todd,, R. Kokka,, M. Urdea,, J. D. Lifson,, M. Piatak, Jr.,, S. Chen,, B. H. Hahn,, M. S. Saag, et al. 1995. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retroviruses 11:353361.
8. Cartwright, C. P. 2006. The changing epidemiology of HIV/AIDS at a Minnesota hospital: impact of demographic change and viral diversity. J. Med. Virol. 78(Suppl. 1):S19S21.
9. Cassol, S.,, T. Salas,, M. J. Gill,, M. Montpetit,, J. Rudnik,, C. T. Sy, and, M. V. O’Shaughnessy. 1992. Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction. J. Clin. Microbiol. 30:30393042.
10. Christo, P. P.,, D. B. Greco,, A. W. Aleixo, and, J. A. Livramento. 2007. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect. Dis. 7:147.
11. Clevenbergh, P.,, J. Durant,, P. Halfon,, P. del Giudice,, V. Mondain,, N. Montagne,, J. M. Schapiro,, C. A. Boucher, and, P. Dellamonica. 2000. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir. Ther. 5:6570.
12. Cohen, C. J.,, S. Hunt,, M. Sension,, C. Farthing,, M. Conant,, S. Jacobson,, J. Nadler,, W. Verbiest,, K. Hertogs,, M. Ames,, A. R. Rinehart, and, N. M. Graham. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579588.
13. Daar, E. S.,, S. Little,, J. Pitt,, J. Santangelo,, P. Ho,, N. Harawa,, P. Kerndt,, J. V. Glorgi,, J. Bai,, P. Gaut,, D. D. Richman,, S. Mandel, and, S. Nichols. 2001. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann. Intern. Med. 134:2529.
14. Damond, F.,, A. Benard,, J. Ruelle,, A. Alabi,, B. Kupfer,, P. Gomes,, B. Rodes,, J. Albert,, J. Boni,, J. Garson,, B. Ferns,, S. Matheron,, G. Chene, and, F. Brun-Vezinet. 2008. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J. Clin. Microbiol. 46:20882091.
15. Delfraissy, J. F.,, P. Flandre,, C. Delaugerre,, J. Ghosn,, A. Horban,, P. M. Girard,, M. Norton,, C. Rouzioux,, A. M. Taburet,, I. Cohen-Codar,, P. N. Van, and, J. P. Chauvin. 2008. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22:385393.
16. Demeter, L. M.,, M. D. Hughes,, R. W. Coombs,, J. B. Jackson,, J. M. Grimes,, R. J. Bosch,, S. A. Fiscus,, S. A. Spector,, K. E. Squires,, M. A. Fischl, and, S. M. Hammer. 2001. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann. Intern. Med. 135:954964.
17. Desire, N.,, A. Dehee,, V. Schneider,, C. Jacomet,, C. Goujon,, P. M. Girard,, W. Rozenbaum, and, J. C. Nicolas. 2001. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J. Clin. Microbiol. 39:13031310.
18. Dickover, R. E.,, S. A. Herman,, K. Saddiq,, D. Wafer,, M. Dillon, and, Y. J. Bryson. 1998. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J. Clin. Microbiol. 36:10701073.
19. Donovan, R. M.,, C. E. Bush,, N. P. Markowitz,, D. M. Baxa, and, L. D. Saravolatz. 1996. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J. Infect. Dis. 174:401403.
20. Dunn, D. T.,, H. Green,, C. Loveday,, A. Rinehart,, D. Pillay,, M. Fisher,, S. McCormack,, A. G. Babiker, and, J. H. Darbyshire. 2005. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J. Acquir. Immune Defic. Syndr. 38:553559.
21. Durant, J.,, P. Clevenbergh,, P. Halfon,, P. Delgiudice,, S. Porsin,, P. Simonet,, N. Montagne,, C. A. Boucher,, J. M. Schapiro, and, P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:21952199.
22. Dyer, J. R.,, C. D. Pilcher,, R. Shepard,, J. Schock,, J. J. Eron, and, S. A. Fiscus. 1999. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 37:447449.
23. Elbeik, T.,, E. Charlebois,, P. Nassos,, J. Kahn,, F. M. Hecht,, D. Yajko,, V. Ng, and, K. Hadley. 2000. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J. Clin. Microbiol. 38:11131120.
24. Erali, M.,, S. Page,, L. G. Reimer, and, D. R. Hillyard. 2001. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J. Clin. Microbiol. 39:21572165.
25. Eshleman, S. H.,, J. Hackett, Jr.,, P. Swanson,, S. P. Cunningham,, B. Drews,, C. Brennan,, S. G. Devare,, L. Zekeng,, L. Kaptue, and, N. Marlowe. 2004. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J. Clin. Microbiol. 42:27112717.
26. Fiscus, S. A.,, D. Brambilla,, L. Grosso,, J. Schock, and, M. Cronin. 1998. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J. Clin. Microbiol. 36:258260.
27. Galli, R.,, L. Merrick,, M. Friesenhahn, and, R. Ziermann. 2005. Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens. J. Clin. Virol. 34:245252.
28. Gao, F.,, E. Bailes,, D. L. Robertson,, Y. Chen,, C. M. Rodenburg,, S. F. Michael,, L. B. Cummins,, L. O. Arthur,, M. Peeters,, G. M. Shaw,, P. M. Sharp, and, B. H. Hahn. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436441.
29. Garcia-Bujalance, S.,, C. Ladron de Guevara,, J. Gonzalez-Garcia,, J. R. Arribas,, F. Zamora, and, A. Gutierrez. 2007. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1. J. Microbiol. Methods 69:384386.
30. Gianotti, N.,, V. Mondino,, M. C. Rossi,, E. Chiesa,, I. Mezzaroma,, N. Ladisa,, G. Guaraldi,, C. Torti,, P. Tarquini,, P. Castelli,, A. Di Carlo,, E. Boeri,, W. Keulen,, P. M. Kenna, and, A. Lazzarin. 2006. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. Clin. Infect. Dis. 42:14701480.
31. Ginocchio, C. C.,, X. P. Wang,, M. H. Kaplan,, G. Mulligan,, D. Witt,, J. W. Romano,, M. Cronin, and, R. Carroll. 1997. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J. Clin. Microbiol. 35:28862893.
32. Griffith, B. P.,, and D. R. Mayo. 2006. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). J. Clin. Virol. 35:197200.
33. Guatelli, J. C.,, R. F. Siciliano,, D. R. Kuritzkes, and, D. D. Richman. 2002. Human immunodeficiency virus, p. 685–729. In D. D. Richman,, R. J. Whitley, and, F. G. Hayden (ed.), Clinical Virology, 2nd ed. ASM Press, Washington, DC.
34. Gueudin, M.,, J. C. Plantier,, F. Damond,, P. Roques,, P. Mauclere, and, F. Simon. 2003. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J. Virol. Methods 113:4349.
35. Gueudin, M.,, J. C. Plantier,, V. Lemee,, M. P. Schmitt,, L. Chartier,, T. Bourlet,, A. Ruffault,, F. Damond,, M. Vray, and, F. Simon. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 44:500505.
36. Hales, G.,, C. Birch,, S. Crowe,, C. Workman,, J. F. Hoy,, M. G. Law,, A. D. Kelleher,, D. Lincoln, and, S. Emery. 2006. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS Clin. Trials 1:e18.
37. Haubrich, R. H.,, C. A. Kemper,, N. S. Hellmann,, P. H. Keiser,, M. D. Witt,, J. G. Tilles,, D. N. Forthal,, J. Leedom,, M. Leibowitz,, J. A. McCutchan, and, D. D. Richman. 2005. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 19:295302.
38. Hertogs, K.,, M. P. de Bethune,, V. Miller,, T. Ivens,, P. Schel,, A. Van Cauwenberge,, C. Van den Eynde,, V. van Gerwen,, H. Azijn,, M. van Houtte,, F. Peeters,, S. Staszewski,, M. Conant,, S. Bloor,, S. Kemp,, B. Larder, and, R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269276.
39. Ho, D. D.,, A. U. Neumann,, A. S. Perelson,, W. Chen,, J. M. Leonard, and, M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123126.
40. Holguin, A.,, M. Lopez,, M. Molinero, and, V. Soriano. 2008. Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J. Clin. Microbiol. 46:29182923.
41. Holodniy, M.,, L. Rainen,, S. Herman, and, B. Yen-Lieberman. 2000. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J. Clin. Microbiol. 38:323326.
42. Hunter, E. 2008. Retroviruses, p. 459–467. In B. W. J. Mahy and, M. H. V. van Regenmortel (ed.), Encyclopedia of Virology, 3rd ed. Elsevier-Academic Press.
43. Jagodzinski, L. L.,, J. D. Cooley,, M. Weber, and, N. L. Michael. 2003. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J. Clin. Microbiol. 41:9981003.
44. Jagodzinski, L. L.,, D. L. Wiggins,, J. L. McManis,, S. Emery,, J. Overbaugh,, M. Robb,, S. Bodrug, and, N. L. Michael. 2000. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J. Clin. Microbiol. 38:12471249.
45. Johnson, J. A.,, J. F. Li,, X. Wei,, J. Lipscomb,, D. Irlbeck,, C. Craig,, A. Smith,, D. E. Bennett,, M. Monsour,, P. Sandstrom,, E. R. Lanier, and, W. Heneine. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatmentnaive populations and associate with reduced treatment efficacy. PLoS Med. 5:e158.
46. Johnson, V. A.,, F. Brun-Vezinet,, B. Clotet,, H. F. Gunthard,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro, and, D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:6268.
47. Kahn, J. O.,, and B. D. Walker. 1998. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339:3339.
48. Lapadula, G.,, I. Izzo,, F. Gargiulo,, G. Paraninfo,, F. Castelnuovo,, E. Quiros-Roldan,, G. Cologni,, F. Ceresoli,, N. Manca,, G. Carosi, and, C. Torti. 2008. Updated prevalence of genotypic resistance among HIV-1 positive patients naive to antiretroviral therapy: a single center analysis. J. Med. Virol. 80:747753.
49. Lew, J.,, P. Reichelderfer,, M. Fowler,, J. Bremer,, R. Carrol,, S. Cassol,, D. Chernoff,, R. Coombs,, M. Cronin,, R. Dickover,, S. Fiscus,, S. Herman,, B. Jackson,, J. Kornegay,, A. Kovacs,, K. McIntosh,, W. Meyer,, N. Michael,, L. Mofenson,, J. Moye,, T. Quinn,, M. Robb,, M. Vahey,, B. Weiser, and, T. Yeghiazarian. 1998. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J. Clin. Microbiol. 36:14711479.
50. Lin, H. H.,, B. K. Gaschen,, M. Collie,, M. El-Fishaway,, Z. Chen,, B. T. Korber,, S. T. Beatrice, and, L. Zhang. 2006. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J. Acquir. Immune Defic. Syndr. 41:399404.
51. Lin, H. J.,, L. E. Myers,, B. Yen-Lieberman,, F. B. Hollinger,, D. Henrard,, C. J. Hooper,, R. Kokka,, S. Kwok,, S. Rasheed,, M. Vahey, et al. 1994. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J. Infect. Dis. 170:553562.
52. Luo, W.,, H. Yang,, K. Rathbun,, C. P. Pau, and, C. Y. Ou. 2005. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J. Clin. Microbiol. 43:18511857.
53. MacArthur, R. D.,, and R. M. Novak. 2008. Maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47:236241.
54. Mallal, S.,, E. Phillips,, G. Carosi,, J. M. Molina,, C. Workman,, J. Tomazic,, E. Jagel-Guedes,, S. Rugina,, O. Kozyrev,, J. F. Cid,, P. Hay,, D. Nolan,, S. Hughes,, A. Hughes,, S. Ryan,, N. Fitch,, D. Thorborn, and, A. Benbow. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358:568579.
55. Marlink, R.,, P. Kanki,, I. Thior,, K. Travers,, G. Eisen,, T. Siby,, I. Traore,, C. C. Hsieh,, M. C. Dia,, E. H. Gueye, et al. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:15871590.
56. Masciotra, S.,, C. Garrido,, A. S. Youngpairoj,, A. McNulty,, N. Zahonero,, A. Corral,, W. Heneine,, C. de Mendoza, and, J. G. Garcia-Lerma. 2007. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21:25032511.
57. McNulty, A.,, C. Jennings,, D. Bennett,, J. Fitzgibbon,, J. W. Bremer,, M. Ussery,, M. L. Kalish,, W. Heneine, and, J. G. Garcia-Lerma. 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J. Clin. Microbiol. 45:517521.
58. Mellors, J. W.,, L. A. Kingsley,, C. R. Rinaldo, Jr.,, J. A. Todd,, B. S. Hoo,, R. P. Kokka, and, P. Gupta. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573579.
59. Mellors, J. W.,, J. B. Margolick,, J. P. Phair,, C. R. Rinaldo,, R. Detels,, L. P. Jacobson, and, A. Munoz. 2007. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 297:23492350.
60. Mellors, J. W.,, A. Munoz,, J. V. Giorgi,, J. B. Margolick,, C. J. Tassoni,, P. Gupta,, L. A. Kingsley,, J. A. Todd,, A. J. Saah,, R. Detels,, J. P. Phair, and, C. R. Rinaldo, Jr. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946954.
61. Mellors, J. W.,, C. R. Rinaldo, Jr.,, P. Gupta,, R. M. White,, J. A. Todd, and, L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:11671170.
62. Meynard, J. L.,, M. Vray,, L. Morand-Joubert,, E. Race,, D. Descamps,, G. Peytavin,, S. Matheron,, C. Lamotte,, S. Guiramand,, D. Costagliola,, F. Brun-Vezinet,, F. Clavel, and, P. M. Girard. 2002. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16:727736.
63. Mylonakis, E.,, M. Paliou,, M. Lally,, T. P. Flanigan, and, J. D. Rich. 2000. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am. J. Med. 109:568576.
64. Nkengasong, J. N.,, C. Bile,, M. Kalou,, C. Maurice,, E. Boateng,, M. Sassan-Morokro,, M. Rayfield,, D. Coulibaly,, A. E. Greenberg, and, S. Z. Wiktor. 1999. Quantification of RNA in HIV type 1 subtypes D and G by NucliSens and Amplicor assays in Abidjan, Ivory Coast. AIDS Res. Hum. Retroviruses 15:495498.
65. Novak, R. M.,, L. Chen,, R. D. MacArthur,, J. D. Baxter,, K. Huppler Hullsiek,, G. Peng,, Y. Xiang,, C. Henely,, B. Schmetter,, J. Uy,, M. van den Berg-Wolf, and, M. Kozal. 2005. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40:468474.
66. O’Brien, T. R.,, W. A. Blattner,, D. Waters,, E. Eyster,, M. W. Hilgartner,, A. R. Cohen,, N. Luban,, A. Hatzakis,, L. M. Aledort,, P. S. Rosenberg,, W. J. Miley,, B. L. Kroner, and, J. J. Goedert. 1996. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 276:105110.
67. O’Brien, W. A.,, K. Grovit-Ferbas,, A. Namazi,, S. Ovcak-Derzic,, H. J. Wang,, J. Park,, C. Yeramian,, S. H. Mao, and, J. A. Zack. 1995. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:10821089.
68. Oliver, A. R.,, S. F. Pereira, and, D. A. Clark. 2007. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay. J. Clin. Microbiol. 45:36163619.
69. Parekh, B.,, S. Phillips,, T. C. Granade,, J. Baggs,, D. J. Hu, and, R. Respess. 1999. Impact of HIV type 1 subtype variation on viral RNA quantitation. AIDS Res. Hum. Retroviruses 15:133142.
70. Patton, J. C.,, E. Akkers,, A. H. Coovadia,, T. M. Meyers,, W. S. Stevens, and, G. G. Sherman. 2007. Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory. Clin. Vaccine Immunol. 14:201203.
71. Perelson, A. S.,, A. U. Neumann,, M. Markowitz,, J. M. Leonard, and, D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:15821586.
72. Perez-Elias, M. J.,, I. Garcia-Arota,, V. Munoz,, I. Santos,, J. Sanz,, V. Abraira,, J. R. Arribas,, J. Gonzalez,, A. Moreno,, F. Dronda,, A. Antela,, M. Pumares,, P. Marti-Belda,, J. L. Casado,, P. Geijos, and, S. Moreno. 2003. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir. Ther. 8:577584.
73. Perrin, L.,, J. M. Pawlotsky,, M. Bouvier-Alias,, C. Sarrazin,, S. Zeuzem, and, G. Colucci. 2006. Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J. Clin. Microbiol. 44:43714375.
74. Petropoulos, C. J.,, N. T. Parkin,, K. L. Limoli,, Y. S. Lie,, T. Wrin,, W. Huang,, H. Tian,, D. Smith,, G. A. Winslow,, D. J. Capon, and, J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920928.
75. Piwowar-Manning, E.,, L. Lugalia,, B. Kafufu, and, J. B. Jackson. 2008. Comparison of results obtained with Amplicor HIV-1 DNA PCR test version 1.5 using 100 versus 500 microliters of whole blood. J. Clin. Microbiol. 46:11041105.
76. Pulido, F.,, J. R. Arribas,, R. Delgado,, E. Cabrero,, J. Gonzalez-Garcia,, M. J. Perez-Elias,, A. Arranz,, J. Portilla,, J. Pasquau,, J. A. Iribarren,, R. Rubio, and, M. Norton. 2008. Lopinavirritonavir monotherapy versus lopinavirritonavir and two nucleosides for maintenance therapy of HIV. AIDS 22:F1F9.
77. Pulido, F.,, R. Delgado,, I. Perez-Valero,, J. Gonzalez-Garcia,, P. Miralles,, A. Arranz,, A. Hernando, and, J. R. Arribas. 2008. Long-term (4 years) efficacy of lopinavir/ ritonavir monotherapy for maintenance of HIV suppression. J. Antimicrob. Chemother. 61:13591361.
78. Raboud, J. M.,, J. S. Montaner,, B. Conway,, S. Rae,, P. Reiss,, S. Vella,, D. Cooper,, J. Lange,, M. Harris,, M. A. Wainberg,, P. Robinson,, M. Myers, and, D. Hall. 1998. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12:16191624.
79. [Reference deleted.]
80. Riddler, S. A.,, R. Haubrich,, A. G. DiRienzo,, L. Peeples,, W. G. Powderly,, K. L. Klingman,, K. W. Garren,, T. George,, J. F. Rooney,, B. Brizz,, U. G. Lalloo,, R. L. Murphy,, S. Swindells,, D. Havlir, and, J. W. Mellors. 2008. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358:20952106.
81. Ross, L.,, R. Boulme,, R. Fisher,, J. Hernandez,, A. Florance,, J. C. Schmit, and, V. Williams. 2005. A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the Antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res. Hum. Retroviruses 21:933939.
82. Rouet, F.,, D. K. Ekouevi,, M. L. Chaix,, M. Burgard,, A. Inwoley,, T. D. Tony,, C. Danel,, X. Anglaret,, V. Leroy,, P. Msellati,, F. Dabis, and, C. Rouzioux. 2005. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43:27092717.
83. Saag, M. S.,, M. Holodniy,, D. R. Kuritzkes,, W. A. O’Brien,, R. Coombs,, M. E. Poscher,, D. M. Jacobsen,, G. M. Shaw,, D. D. Richman, and, P. A. Volberding. 1996. HIV viral load markers in clinical practice. Nat. Med. 2:625629.
84. Saitoh, A.,, K. Hsia,, T. Fenton,, C. A. Powell,, C. Christopherson,, C. V. Fletcher,, S. E. Starr, and, S. A. Spector. 2002. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J. Infect. Dis. 185:14091416.
85. Schumacher, W.,, E. Frick,, M. Kauselmann,, V. Maier-Hoyle,, R. van der Vliet, and, R. Babiel. 2007. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 38:304312.
86. Sebire, K.,, K. McGavin,, S. Land,, T. Middleton, and, C. Birch. 1998. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J. Clin. Microbiol. 36:493498.
87. Segondy, M.,, J. Izopet,, I. Pellegrin,, B. Montes,, B. Dumon,, C. Pasquier,, M. Peeters,, H. J. Fleury,, J. Puel, and, J. Reynes. 1998. Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. J. Clin. Microbiol. 36:33923395.
88. Sharp, P. M.,, E. Bailes,, R. R. Chaudhuri,, C. M. Rodenburg,, M. O. Santiago, and, B. H. Hahn. 2001. The origins of acquired immune deficiency syndrome viruses: where and when? Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:867876.
89. Staprans, S. I.,, B. L. Hamilton,, S. E. Follansbee,, T. Elbeik,, P. Barbosa,, R. M. Grant, and, M. B. Feinberg. 1995. Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182:17271737.
90. Sterling, T. R.,, R. E. Chaisson,, J. Keruly, and, R. D. Moore. 2003. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J. Infect. Dis. 188:16591665.
91. Swanson, P.,, V. Holzmayer,, S. Huang,, P. Hay,, A. Adebiyi,, P. Rice,, K. Abravaya,, S. Thamm,, S. G. Devare, and, J. Hackett, Jr. 2006. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J. Virol. Methods 137:184192.
92. Taylor, B. S.,, M. E. Sobieszczyk,, F. E. McCutchan, and, S. M. Hammer. 2008. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358:15901602.
93. Thomson, M. M.,, and R. Najera. 2005. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev. 7:210224.
94. Tsibris, A. M.,, M. Sagar,, R. M. Gulick,, Z. Su,, M. Hughes,, W. Greaves,, M. Subramanian,, C. Flexner,, F. Giguel,, K. E. Leopold,, E. Coakley, and, D. R. Kuritzkes. 2008. In vivo emergence of vicriviroc resistance in an HIV-1 subtype C-infected subject. J. Virol. 82:82108214.
95. Vitone, F.,, D. Gibellini,, P. Schiavone, and, M. C. Re. 2005. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J. Clin. Virol. 33:194200.
96. Wang, K.,, R. Samudrala, and, J. E. Mittler. 2004. Antivirogram or PhenoSense: a comparison of their reproducibility and an analysis of their correlation. Antivir. Ther. 9:703712.
97. Waters, L.,, S. Mandalia,, P. Randell,, A. Wildfire,, B. Gazzard, and, G. Moyle. 2008. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin. Infect. Dis. 46:16171623.
98. Weinstein, M. C.,, S. J. Goldie,, E. Losina,, C. J. Cohen,, J. D. Baxter,, H. Zhang,, A. D. Kimmel, and, K. A. Freedberg. 2001. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134:440450.
99. Whitcomb, J. M.,, W. Huang,, S. Fransen,, K. Limoli,, J. Toma,, T. Wrin,, C. Chappey,, L. D. Kiss,, E. E. Paxinos, and, C. J. Petropoulos. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 co-receptor tropism. Antimicrob. Agents Chemother. 51:566575.
100. Yao, J. D.,, J. J. Germer,, F. Damond,, B. Roquebert, and, D. Descamps. 2008. Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays. J. Clin. Microbiol. 46:834.
101. Yen-Lieberman, B.,, D. Brambilla,, B. Jackson,, J. Bremer,, R. Coombs,, M. Cronin,, S. Herman,, D. Katzenstein,, S. Leung,, H. J. Lin,, P. Palumbo,, S. Rasheed,, J. Todd,, M. Vahey, and, P. Reichelderfer. 1996. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J. Clin. Microbiol. 34:26952701.
102. Youngpairoj, A. S.,, S. Masciotra,, C. Garrido,, N. Zahonero,, C. de Mendoza, and, J. G. Garcia-Lerma. 2008. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4°C. J. Antimicrob. Chemother. 61:12171220.
103. Zhuang, J.,, A. E. Jetzt,, G. Sun,, H. Yu,, G. Klarmann,, Y. Ron,, B. D. Preston, and, J. P. Dougherty. 2002. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J. Virol. 76:1127311282.


Generic image for table

Current FDA-approved antiretroviral drugs

Citation: Caliendo A, Kraft C. 2011. Molecular Detection and Characterization of HIV-1, p 541-556. In Persing D, Tenover F, Tang Y, Nolte F, Hayden R, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555816834.ch35
Generic image for table

FDA-approved molecular tests for quantification of HIV-1 RNA

Citation: Caliendo A, Kraft C. 2011. Molecular Detection and Characterization of HIV-1, p 541-556. In Persing D, Tenover F, Tang Y, Nolte F, Hayden R, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555816834.ch35
Generic image for table

Assays for resistance testing

Citation: Caliendo A, Kraft C. 2011. Molecular Detection and Characterization of HIV-1, p 541-556. In Persing D, Tenover F, Tang Y, Nolte F, Hayden R, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555816834.ch35

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error